A 'The Office' spinoff, 'The Paper,' premieres on Peacock in 2025, following a struggling Ohio newspaper with an optimistic new editor-in-chief and an unconventional newsroom staff.
Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise despite higher R&D expenses and a decline in operating margin.
Decades after 9/11, DNA analysis identifies three more victims, providing closure to families and highlighting the role of science in honoring the tragedy's victims.
A 'The Office' spinoff, 'The Paper,' premieres on Peacock in 2025, following a struggling Ohio newspaper with an optimistic new editor-in-chief and an unconventional newsroom staff.
Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise despite higher R&D expenses and a decline in operating margin.
Decades after 9/11, DNA analysis identifies three more victims, providing closure to families and highlighting the role of science in honoring the tragedy's victims.
